Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with compatriot Chengdu Ucello Biotechnology Co., Ltd. The collaboration aims to develop universal cell therapies by integrating Eureka’s CellSep series cell preparation system and its world-class EuLV-based lentivirus production system based on stable cell lines into Ucello’s allogeneic universal chimeric antigen receptor (CAR)-T cell technology platform. Financial details of the partnership were not disclosed.
Partnership Focus and Objectives
Ucello, which specializes in the research and development, manufacturing, and operation of allogeneic universal CAR-T therapies, brings to the partnership its in-house developed UC101. This therapy demonstrated promising therapeutic effects in a Phase II study for acute B lymphocytic leukemia. Eureka, a specialist in cell and gene therapy, contributes its self-developed CellSep series cell processing system, which is capable of PBMC isolation, screening and activation, gene transduction, concentration washing, and preparation bagging, among other processes.
Future Outlook
The partnership between Eureka and Ucello is expected to accelerate the development and commercialization of universal cell therapies. By combining Ucello’s expertise in allogeneic CAR-T therapies with Eureka’s advanced cell processing technologies, the collaboration aims to enhance the efficiency and efficacy of universal cell therapy development, ultimately benefiting patients in need of innovative treatments.-Fineline Info & Tech
